Puma Biotechnology, INC.: management transactions · United States · SEC (Form 4)

About Puma Biotechnology, INC.

Puma Biotechnology, Inc. is a U.S.-listed biopharmaceutical company trading on the NASDAQ under the ticker PBYI. Headquartered in Los Angeles, California, in the United States, the company focuses on acquiring, developing, and commercializing novel cancer therapeutics. Its strategy is that of a specialty oncology biotech rather than a broad diversified pharmaceutical group: Puma tends to license or in-license assets with clinical precedent, advance them through development, and then build commercial value through focused execution. The company’s current corporate form traces back to 2010, and founder Alan H. Auerbach has remained central to the business since inception. ([pumabiotechnology.com](https://www.pumabiotechnology.com/about/overview.html?utm_source=openai)) Puma’s core commercial asset is NERLYNX® (neratinib), an oral oncology therapy that remains the company’s primary revenue driver. Recent company disclosures show that product revenue is derived overwhelmingly from NERLYNX sales, supplemented by royalty income from select international arrangements. In addition to maintaining the NERLYNX franchise, Puma has added a second growth pillar with alisertib, an asset in-licensed from Takeda in 2022. The drug is now being advanced in clinical programs such as ALISCA™-Breast1 and ALISCA™-Lung1, which target chemotherapy-naïve HER2-negative, hormone receptor-positive metastatic breast cancer and extensive-stage small cell lung cancer. For investors, that is an important point: Puma remains highly dependent on one marketed product, but it is also working to expand its pipeline and reduce single-asset concentration over time. ([investor.pumabiotechnology.com](https://investor.pumabiotechnology.com/news-releases/news-release-details/puma-biotechnology-reports-fourth-quarter-and-full-year-2025)) From a competitive standpoint, Puma occupies a niche position in targeted oncology. NERLYNX is established in HER2-related breast cancer care, where it competes in a sophisticated but crowded treatment landscape. Puma does not have the scale of a major global pharma company; instead, its edge lies in specialization, a commercialized revenue base, and disciplined capital allocation. Geographically, the business is still primarily U.S.-anchored, although the company also benefits from international sublicensing and royalty streams, including activity referenced in recent disclosures from Asia. ([investor.pumabiotechnology.com](https://investor.pumabiotechnology.com/news-releases/news-release-details/puma-biotechnology-reports-fourth-quarter-and-full-year-2025)) Recent milestones have been constructive. Puma reported 2025 results showing a third consecutive year of profitability, total revenue of $228.4 million, and positive operating cash flow. Management also guided to continued profitability in 2026 and highlighted several clinical readouts for alisertib expected over the next 12 months. For international investors monitoring U.S. healthcare names, PBYI presents a mix of commercial-stage stability, product concentration risk, and clinical upside tied to its oncology pipeline. ([investor.pumabiotechnology.com](https://investor.pumabiotechnology.com/news-releases/news-release-details/puma-biotechnology-reports-fourth-quarter-and-full-year-2025))